(Q36815013)

16 August 2017

Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis (English)

1 reference

16 August 2017

0 references

hepatocellular carcinoma

1 reference

1 reference

4

Raymond T Chung

1 reference

16 August 2017

Joel R Pekow

1

1 reference

16 August 2017

Atul K Bhan

series ordinal

2

1 reference

16 August 2017

Hui Zheng

series ordinal

3

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

16 August 2017

1 reference

16 August 2017

109

1 reference

16 August 2017

12

1 reference

16 August 2017

2490-2496

1 reference

Hepatitis C virus core protein induces hepatic steatosis in transgenic mice

16 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

Rising incidence of hepatocellular carcinoma in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

The increasing incidence of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Obesity and diabetes as a risk factor for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Risk factors for hepatocellular carcinoma in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Non-alcoholic fatty liver disease: an emerging pathological spectrum

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Obesity and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Prevalence of and risk factors for hepatic steatosis in Northern Italy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Impact of steatosis on progression of fibrosis in patients with mild hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

HCV RNA levels in hepatocellular carcinomas and adjacent non-tumorous livers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Carbohydrate and lipid metabolism in cirrhosis. Evidence that hepatic uptake of gluconeogenic precursors and of free fatty acids depends on effective hepatic flow

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Mitochondrial abnormalities in non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Steatosis and intrahepatic hepatitis C virus in chronic hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

IKK-beta links inflammation to obesity-induced insulin resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22701

7 January 2021

Identifiers

DOI

10.1002/CNCR.22701

1 reference

release_y2pke272traofg2oabqnmv2zpm

16 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/y2pke272traofg2oabqnmv2zpm

24 November 2022

mapped directly with Wikidata item

1 reference